Welcome to our dedicated page for Kodiak Sciences SEC filings (Ticker: KOD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kodiak Sciences Inc. filings document a Nasdaq-listed biotechnology issuer developing retinal medicines through its ABC Platform and related biologic programs. Recent Form 8-K reports record financial results, business highlights, clinical disclosures for Zenkuda, KSI-501 and KSI-101, and capital-structure events involving common stock.
Proxy materials describe annual meeting matters, shareholder voting procedures, executive compensation and equity award disclosures. Offering-related 8-K disclosures record the completed underwritten public offering of common stock, underwriting agreement terms, registered security details and related exhibits.
Kodiak Sciences Inc. reported a compensation grant to Chief Financial Officer John A. Borgeson of stock options covering 66,500 shares of common stock on July 15, 2026. The options have an exercise price of $42.42 per share, expire on July 14, 2036, and were fully unvested at grant. One-forty-eighth of the shares vest one month after July 1, 2026, with the remaining shares vesting in forty-seven equal monthly installments thereafter, subject to his Continuous Service under the 2018 Equity Incentive Plan.
Kodiak Sciences Inc. reported that Chairman, CEO and 10% owner Victor Perlroth received a grant of stock options covering 100,000.0000 shares of Common Stock at an exercise price of $42.4200 per share. These options expire on 2036-07-14 and vest monthly beginning after July 1, 2026, subject to his Continuous Service.
Kodiak Sciences Inc. director Yang Taiyin received a new stock option grant as part of equity compensation. The award covers 17,731 stock options for common stock at an exercise price of $38.96 per share, with no cash paid at grant.
All 17,731 options will vest in a single tranche on the earlier of June 30, 2027 or one day before Kodiak Sciences’ next annual shareholder meeting after the grant date, provided Yang continues serving on the board through the applicable vesting date. Following this grant, Yang holds 17,731 stock options directly.
Kodiak Sciences Inc. director Robert Profusek received a grant of stock options covering 17,731 shares of common stock. The options have an exercise price of $38.96 per share and expire on June 29, 2036.
All 17,731 option shares vest in full on the earlier of June 30, 2027 or one day before the company’s next annual meeting after the grant date, as long as he continues serving on the board through that vesting date. Following this grant, he holds 17,731 derivative securities directly.
Kodiak Sciences Inc. director Richard S. Levy received a stock option grant covering 17,731 shares of common stock. The option has an exercise price of $38.96 per share and expires on June 29, 2036. Following this grant, he holds options for 17,731 shares directly.
All 17,731 option shares will vest in a single tranche on the earlier of June 30, 2027 or one day before Kodiak Sciences’ next annual shareholder meeting after the grant date, provided Levy continues to serve on the board of directors through the applicable vesting date.
Kodiak Sciences Inc. director Bassil I. Dahiyat received a grant of stock options covering 17,731 shares of common stock. The options have an exercise price of $38.96 per share and expire on June 29, 2036.
All 17,731 option shares vest in a single tranche on the earlier of June 30, 2027 or one day before Kodiak’s next annual shareholder meeting after the grant date, provided Dahiyat continues to serve on the board through that vesting date.
Kodiak Sciences director Charles A. Bancroft received a new stock option grant, giving him the right to buy 17,731 shares of common stock at an exercise price of $38.96 per share. These options were granted at no cost to him on June 30, 2026.
The entire option grant vests in a single tranche on the earlier of June 30, 2027 or one day before Kodiak Sciences’ next annual shareholder meeting after the grant date, as long as Bancroft continues to serve on the company’s board of directors through that vesting date. After this grant, he holds options for 17,731 shares directly.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
Kodiak Sciences Inc. reported a compensation-related insider transaction involving a grant of non-qualified stock options linked to entities associated with Julian and Felix Baker. On June 30, 2026, Felix J. Baker, serving as a director, received a grant of 17,731 stock options exercisable into Kodiak common stock at a strike price of $38.96 per share under the company’s 2018 Equity Incentive Plan. The options vest on the earlier of the first anniversary of the grant or one day before the next annual stockholder meeting, provided he continues serving on the board, and they expire on June 29, 2036. The grant is reported for multiple Baker-affiliated funds because each has an indirect proportionate pecuniary interest, while Baker Bros. Advisors LP holds voting and dispositive power and the Baker parties and the adviser disclaim beneficial ownership beyond their economic interest.
Kodiak Sciences Inc. Chief Financial Officer John A. Borgeson reported an exercise-and-sell transaction in company stock. He exercised stock options for 30,000 shares of common stock at an exercise price of $1.04 per share and acquired those shares. On the same date, he sold a total of 30,000 shares of common stock in open-market transactions at weighted-average prices of $34.01 and $34.67 per share, as disclosed in two sale entries. These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025. After these transactions, he directly holds 211,930 shares of Kodiak Sciences common stock.
Kodiak Sciences Inc. reported results of its 2026 annual meeting of stockholders held on June 2, 2026. Stockholders representing 55,026,544 shares, or 88.53% of the common stock entitled to vote, were present.
Three Class II directors — Charles A. Bancroft, Bassil I. Dahiyat, Ph.D., and Taiyin Yang, Ph.D. — were elected to serve until the 2029 annual meeting or until their successors are elected and qualified. Support ranged from 38,940,529 to 49,192,610 votes "for," with broker non-votes recorded on each item.
Stockholders approved, on an advisory basis, the compensation of the named executive officers, with 49,157,143 votes for, 323,196 against and 21,005 abstentions. They also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 54,716,676 votes for, 52,962 against and 256,906 abstentions.